by Raynovich Rod | Feb 12, 2018 | Biopharmaceuticals
Large Cap Biopharmaceuticals Performance Part 1- After Correction Technicals: we are holding the December 2017 bottom but 2018 gains on some indices have been wiped out with peak values on Jan. 26. The FBT was the top performing ETF in 2018 YTD. Many of our picks have...
by Raynovich Rod | Feb 1, 2018 | Biopharmaceuticals, Macro
Profit Taking Hits Biotech Stocks Disruption Coming to Healthcare? Another Round of Sector Rotation? The biotech sector hit a wall after breaking through to new highs last week. The major news that sparked profit taking on Tuesday was that Amazon, Berkshire Hathaway...
by Raynovich Rod | Jan 26, 2018 | Biopharmaceuticals
Update-1 10:40am EST, NASDAQ off 0.75%, S&P 500 off 0.82% Caution in biotech and healthcare stocks with disruptive announcement from J.P.Morgan, Amazon and Berkshire Hathaway with XLV down 2%. The three companies announced Tuesday that they would form an...
by Raynovich Rod | Jan 22, 2018 | Biopharmaceuticals
Update-1 Jan 23, 2018… Biotech Breakout Rally Continues The biotech rally cruised on to the second day with the smaller cap, equal weighted XBI moving up 2% to $95.82 a 12 month high. The large cap weighted IBB followed up 1.12% to $116.81 also a 12 month high....
by Raynovich Rod | Jan 16, 2018 | Biopharmaceuticals
Update-1… January 17 Dow Rallies 300 Points Market returns to the momentum mode with tax reform theme, M&A and upbeat earnings. Apple (AAPL)was a driver as a potential job creator up 1.6% on repatriation of foreign cash and contributing $350B to economy. ...
by Raynovich Rod | Jan 15, 2018 | Biopharmaceuticals
Large Cap Biopharmaceuticals 2018 Performance after J.P.Morgan Healthcare Conference Here is an update of Large Cap Biopharmaceuticals Performance over the past 12 months. These numbers will be updated after all 2017 financials have been reported. Note that the IBB...
by Raynovich Rod | Jan 10, 2018 | Biopharmaceuticals
Sluggish Early Trading in Biotech Tracks NASDAQ Down 0.14%% Promising Year for M&A and Tax Cuts Improving Bottom Line There is a little follow-on to Tuesday’s rally bringing prices for major ETFs above where they were last week. The biotech screen reverted...
by Raynovich Rod | Jan 9, 2018 | Biopharmaceuticals
Weak Start for Biotech Stocks on 1/8/18-Red Screen Day Positive Updates on BIIB CELG GILD etc Biotech ETFs Firm Up about 1.5% Tuesday AM JPMorgan Healthcare Conference Biotech stocks abruptly sold off at the market open yesterday with the XBI down 2% to the $85.31...
by Raynovich Rod | Jan 2, 2018 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Rayno Life Science Portfolio
2/28/18 Update Tape looks sluggish at major resistance. Downgrade to HOLD on Celgene (CELG). Bad regulatory news on relapsing multiple sclerosis drug ozanimod. 2/2/18 Update After Sell-Off Cautious on Amgen (AMGN) after earnings release but looks better than the IBB...
by Raynovich Rod | Dec 20, 2017 | 2024 Rayno Tools and Diagnostics Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Clinical Diagnostics and Tools: Big Winners Are In Genomics and Personalized Medicine Slower growth in routine clinical diagnostics, tools are favored. Hologic has a unique business model for women’s health and diagnostics. Gene sequencing is important for...
